Bill Langbein

/Bill Langbein

ADMA Biologics Receives a Split FDA Decision on BIVIGAM

ADMA Biologics (NASDAQ:ADMA), a company specializing in the manufacturing and development [...]

ADMA Biologics (NASDAQ:ADMA) December Catalyst: PDUFA for BIVIGAM

SanaCurrents assigns a pivotal sentiment the FDA will approve the [...]

Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares

Catalyst Biosciences, Inc. (NASDAQ:CBIO) , a company that is developing improved [...]

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X

3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is [...]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial

December catalyst, lymphoma phase IIb trial SanaCurrents assigns a pivotal [...]

SanaCurrents BioTech Research Service Inaugural Reports on EIDX and GLMD

Last week, Galmed Pharmaceuticals  (NASDAQ:GLMD) shares climbed as high as [...]

Update on Eidos Therapeutics after Positive Phase II Results

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as [...]

Galmed (GLMD) – November Catalyst: Aramchol

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [...]